ArticleFacts, views & vision in ObGyn2020
Treatment algorithm in patients with ovarian cancer.
Article in Facts, views & vision in ObGyn, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 21 citations in OpenAlex.
- Recurrence-free survival is prolonged in high-grade serous ovarian cancer with high PD-L1 expression.BMC cancer · 2026Article
- Absence of synergistic effects by CDK12/13 inhibition in combination with cisplatin or olaparib in ovarian cancer cells.Scientific reports · 2026Article
- Perspectives of positron emission tomography with 2-deoxy-2-fluorine-18-flu-d-glucose (18fdg-pet) in predicting the histological response of high grade epithelial ovarian cancer to neoadjuvant chemotherapy. A primary descriptive study.American journal of nuclear medicine and molecular imaging · 2026Article
- Platinum-rechallenge in epithelial ovarian cancer relapsing within 6 months after first-line treatment: a propensity score matching analysis.International journal of clinical oncology · 2025Observational
- Treatment of ovarian cancer: From the past to the new era (Review).Oncology letters · 2025Review
- The compositional behavior of the human T cell receptor repertoire in ovarian cancer compared to healthy donors.Scientific data · 2025Article
- Fluorescence-Guided Surgery to Detect Microscopic Disease in Ovarian Cancer: A Systematic Review with Meta-Analysis.Cancers · 2025Review
- Pregnancy after advanced ovarian cancer with spontaneous uterine rupture in second trimester: A case report and review of the literature.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2025Review
- Patient-derived ovarian cancer organoid carries immune microenvironment and blood vessel keeping high response to cisplatin.MedComm · 2024Article
- Cytoreductive surgery plus chemotherapy versus chemotherapy alone for recurrent epithelial ovarian cancer.The Cochrane database of systematic reviews · 2024Article
- Ovarian cancer is detectable from peripheral blood using machine learning over T-cell receptor repertoires.Briefings in bioinformatics · 2024Article
- Article
- Review
- Gynecologic oncology tumor board: the central role of the radiologist.Abdominal radiology (New York) · 2023Review
- Molecular and phenotypic characteristics influencing the degree of cytoreduction in high-grade serous ovarian carcinomas.Cancer medicine · 2023Article
- Homologous recombination repair deficiency (HRD) testing in newly diagnosed advanced-stage epithelial ovarian cancer: A Belgian expert opinion.Facts, views & vision in ObGyn · 2022Article
- miR-93-5p suppresses ovarian cancer malignancy and negatively regulate CCND2 by binding to its 3'UTR region.Discover oncology · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Most ovarian cancer patients are diagnosed only at advanced stages when survival outcomes are worse, andwhen therapeutic decisions might prove challenging. The fundamental treatment for women with ovarian cancerincludes debulking surgery whenever possible and appropriate systemic therapy (chemotherapy, targeted andantiangiogenic agents). In the last few years, knowledge about histological and molecular characteristics of ovariancancer subtypes and stages has increased considerably. This has enabled the development and improvement ofseveral options for the diagnosis and treatment of ovarian cancer in a patient-tailored approach. Accordingly,therapeutic decisions are guided by the characteristics of the patient and the tumour, especially the molecularfeatures of the cancer subtype and disease stage. Particularly relevant are the advances in early genetic testing ofgermline and somatic mutations involved in DNA repair, and the clinical development of targeted agents. In orderto implement the best individual medical strategies, in this article, we present an algorithm of treatment options,including recently developed targeted agents, for primary and recurrent ovarian cancer patients in Belgium.
Indexed as
Identifiers
33123697PMC7580261W3095511752What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.